Stock Analysts

Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss

Arena Pharmaceuticals, Inc. ( ARNA ) fell approximately 3.7% after the company reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014 wider than the Zacks Consensus Estimate of loss of 11 cents. Arena had reported earnings of 17 cents per share in the year-ago quarter […]

Stock Analysts

Fortress Investment Up on Earnings Beat & Special Dividend

Shares of Fortress Investment Group LLC ( FIG ) gained 1.5% after it reported second-quarter 2014 pre-tax distributable earnings of 39 cents per share, up 30% year over year. Moreover, results outpaced the Zacks Consensus Estimate of 34 cents. The declaration of a special dividend along with the earnings release also helped boost investors’ confidence. […]

Economic Data

Q3 Guidance And Beyond Holds The Key – Economic Highlights

After the market sell-off last week, the S&P 500 is now down 3% from its rally-highs a month ago. A Goldilocks jobs report, which is not now expected to sway the Fed into any new drastic policy changes, was a bit of good news Friday, even though the S&P was hit by a mid-day swoon it wouldn’t quite recover from. Solid Q2 earnings across most sectors this season justified the long run-up in the stock market, and we had been expecting stronger quarterly data. […]

Stock Analysts

SurModics Beats on Earnings in Q3, Guidance Revised

SurModics ’ ( SRDX ) third quarter fiscal 2014 (ended Jun 30, 2014) earnings of 27 cents per share beat the Zacks Consensus Estimate by 4 cents. The third quarter fiscal 2014 earnings increased 22.7% from the year-ago period. Shares of the company reacted positively to the earnings report. […]